Activella

What it is

Activella is a brand-name once-daily oral tablet that combines two hormones: 17β-estradiol (bioidentical estrogen) and norethindrone acetate (a synthetic progestin). It is FDA-approved for moderate-to-severe vasomotor symptoms of menopause, moderate-to-severe symptoms of vulvar and vaginal atrophy, and prevention of postmenopausal osteoporosis in women with a uterus.

Activella is available in two strengths: 1 mg estradiol / 0.5 mg norethindrone acetate, and a lower-dose 0.5 mg estradiol / 0.1 mg norethindrone acetate. Both Activella doses are taken continuously — one tablet daily, no placebo week.

Because Activella contains both estrogen and progestogen in a single tablet, it replaces the older two-drug regimen of taking Estrace (or generic estradiol) plus a separate nightly progesterone pill. An authorized generic — Amabelz — is bioequivalent and often significantly less expensive.

Activella is a modern, bioidentical-estrogen alternative to older combined oral HRT products like Prempro (which uses conjugated equine estrogens plus medroxyprogesterone). Estradiol-based products like Activella are more commonly prescribed in current U.S. practice.

How it works

The estradiol component of Activella is absorbed through the gastrointestinal tract, passes through the liver, and reaches the bloodstream where it stabilizes the hypothalamic thermoregulatory center. This is the mechanism that reduces hot flashes and night sweats — typically by 75–80% within 8–12 weeks.

Estradiol also restores vaginal epithelium and lubrication, preserves bone mineral density (an FDA-approved indication for Activella), stabilizes mood for many patients, and improves sleep by reducing nocturnal vasomotor episodes.

The norethindrone acetate component provides endometrial protection. In a woman with a uterus, unopposed estrogen increases the risk of endometrial hyperplasia and endometrial cancer; adding a progestogen suppresses that risk. Activella registration trials demonstrated endometrial safety over 12 months of continuous daily use.

Who it's for

• Postmenopausal women with a uterus who prefer a once-daily oral pill over a patch
• Women with moderate-to-severe hot flashes, night sweats, sleep disruption, or genitourinary symptoms
• Postmenopausal women at elevated risk of osteoporosis without contraindication to estrogen
• Women who tolerated norethindrone-based oral contraceptives well in the past
• Patients who prefer bioidentical estradiol over conjugated equine estrogens (Prempro, Premarin)

Who should not take it

• Personal history of breast cancer or other estrogen-sensitive cancer
• Active or recent blood clot, stroke, transient ischemic attack, or heart attack
• Elevated baseline VTE (blood clot) risk — transdermal (CombiPatch) is preferred over oral
• Migraine with aura (transdermal is preferred over oral)
• Active liver disease or history of cholestatic jaundice
• Undiagnosed abnormal vaginal bleeding
• Known or suspected pregnancy
• Women who have had a hysterectomy (estrogen alone is appropriate)

Common side effects

• Breast tenderness, mild bloating, or headache during the first 4–6 weeks — the most common Activella side effects.
• Nausea, particularly if taken on an empty stomach (take with food).
• Spotting or breakthrough bleeding, especially during the first 3–6 months of continuous daily dosing.
• Mood changes in a subset of patients sensitive to synthetic progestins; switching to estradiol plus bioidentical micronized progesterone (Prometrium) is usually the next step if this occurs.
• Fluid retention or mild leg swelling.
• Skin changes (chloasma / melasma) in a small percentage of patients — more common in women who developed it during pregnancy or on oral contraceptives.

Evidence summary

• FDA-approved indications: moderate-to-severe vasomotor symptoms of menopause, moderate-to-severe symptoms of vulvar and vaginal atrophy, and prevention of postmenopausal osteoporosis in women with a uterus.
• Activella pivotal trials: ~80% reduction in weekly hot flash frequency by week 12 versus placebo; sustained bone mineral density preservation over 2 years; endometrial hyperplasia rates equivalent to combined placebo over 12 months.
• NAMS 2022 Hormone Therapy Position Statement: continuous combined oral HRT is an appropriate first-line option for postmenopausal women with a uterus at low cardiovascular and thrombotic risk who prefer oral dosing.
• Endocrine Society 2015: oral combined HRT is associated with a modest increase in VTE risk vs transdermal — considered when selecting the route.

Brand-name vs compounded

Activella is an FDA-approved brand-name product. Many Kindr patients use compounded alternatives prepared by a state-licensed 503A pharmacy when a custom dose, custom combination, or different delivery form is clinically preferable. Both pathways are available through Kindr — your provider will recommend based on your individual needs.

FAQ

Sources

• NAMS 2022 Hormone Therapy Position Statement
• ACOG: Menopausal Symptom Management
• U.S. Food & Drug Administration
• Activella FDA prescribing information

Other medications

This page is educational and is not a substitute for a clinical evaluation. Whether any medication is appropriate for you depends on your full medical history. Kindr providers make individualized prescribing decisions during a clinical visit.